Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer 1 non-small cell lung cancer 2,3 help 1 beta (IL-1ß) in pro-tumor inflammation i n lung cancer, with multiple clinical trials investigating canakinumab in 2 -5 Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoin...
Source: finanznachrichten.de